Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$761.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Marino Garcia
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 92
- Beta
- 0.08
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 72.05
Financials
Revenue
$761.0K-35.1%Net Income
$-50.22MEBITDA
$-50.18MFree Cash Flow
$-49.16MEPS (diluted)
$-0.90Shares Outstanding (diluted)
56.03M+2434.5%Operating Expenses
$62.24MCash & Debt
$886.81MReturn of Capital
$0.00Revenue by Segment (annual)
$2.04MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.04M | $-162.34M | $-4.20 |
| 2024 | $6.24M | $-84.97M | $-2.55 |
| 2023 | $2.83M | $-43.55M | $-8.45 |
| 2022 | $6.42M | $-28.48M | $-7.60 |
| 2021 | $1.48M | $-13.11M | $-3.82 |
| 2020 | $0.00 | $-74.94M | $-27.30 |
| 2019 | $0.00 | $-76.77M | $-33.18 |
| 2018 | $0.00 | $-57.52M | $-27.62 |
| 2017 | $0.00 | $-35.49M | $-16.05 |
| 2016 | $0.00 | $-9.43M | $-4.27 |
Valuation
DNTHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·7d ago·Neutral
…prubart Data Presentations Planned for 2026 AANEM Annual Meeting NEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced one oral presentation and four poster presentations for claseprubart at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meet…
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - News (RSS)seekingalpha·30d ago·Neutral
Dianthus: Hold, Based On Competitor C1s' CIDP Setback And Continued Claseprubart Advancement
View source ↗ - News (RSS)yahoo·30d ago·Negative
Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen
View source ↗ - News (RSS)seekingalpha·42d ago·Positive
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case
View source ↗ - Newsseekingalpha.com·42d ago·Positive
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case Dianthus Therapeutics is building a neuromuscular franchise around claseprubart, differentiated by clinical profile and financial independence. DNTH holds ~$1.2B in cash and investments, supporting multiple late-stage programs and reducing funding event risk through 2030. Claseprubart's dosing convenience, pathway selectivity, and strong early data set it apart amid evolving competitive dynamics, especially after Sanofi's setback.
View source ↗ - News (RSS)investing·52d ago·Neutral
Dianthus Therapeutics stock hits 52-week high at 114.64 USD
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.94 per share
Typical surprise -2.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-0.90 vs $-0.85miss
- Tue, May 5$-0.85 vs $-1.17beat
- Mon, Mar 9$-1.43 vs $-0.98miss
- Wed, Nov 5$-0.97 vs $-0.86miss
- Thu, Aug 7$-0.88 vs $-0.86miss
- Mon, May 12$-0.82 vs $-0.86beat
Estimates and results for DNTH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DNTH officers and directors.
- Bought
- —
- Sold
- $43.8m
0 trades
47 trades
- Carr Edwardsold
- Carr Edwardsold
- Carr Edwardsold
- Carr Edwardsold
- Carr Edwardsold
- Randhawa Simratsold
- Randhawa Simratsold
- Randhawa Simratsold
53 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DNTH.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.